Contraceptive Drugs Market Size, Share, Trends, Growth and Forecast Report 2021-2027

Description

The global Contraceptive Drugs market garnered revenue around USD 16,426.15 million in 2020 and projected to reach USD 26,514.23 million in 2027, with at a compound annual growth rate (CAGR) 7.8% throughout the estimate period from 2021 to 2027. Contraception is a method to prevent unwanted pregnancy, control birth rate, and reduce the risk of sexually transmitted diseases (STDs). Contraception involves the use of drugs in the form of oral pills, injectable contraceptives, and topical contraceptives. These drugs are used among women of childbearing age after puberty and before menopause, that is, between 15 and 44 years of age.  Contraceptive drugs are used by a set of end users to prevent pregnancy & STIs and for birth control & family planning. Increase in concerns about family planning and necessity to prevent unintended pregnancy are some of the major factors driving the growth of the global contraceptive drugs market. Furthermore, upsurge in the use of contraception among young women and increase in higher educational attainment promote the market growth. Furthermore, health problems allied with teenage pregnancies, surge in awareness regarding modern contraception methods, and increase in the usage of oral pills as a crucial technique to avert unplanned pregnancy are expected to propel the growth of the market in the years to come. However, health risks associated with the use of contraceptives, accessibility of alternate contraceptive methods, and less social acceptance negatively impact the contraceptive drugs market growth.

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Contraceptive Drugs market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Contraceptive Drugs market growth.

The global Contraceptive Drugs market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

The key players profiled in this report include Agile Therapeutics, Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Johnson & Johnson, Piramal Healthcare, Mylan N.V., Pfizer Inc., Novartis AG and Teva Pharmaceutical Industries Ltd. Other players operating in the market are HLL Lifecare ltd,  and Sanofi.

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Product 

·         Oral Contraceptive Pills

·         Injectable Contraceptives

·         Topical Contraceptives

By Age Group

·         15–24 years

·         25–34 years

·         35–44 years

·         Above 44 years

By End User 

·         Homecare

·         Hospitals

·         Clinics

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:

 

North America

United States

Canada

 

Europe

Germany

United Kingdom

Italy

France

Rest of EU

 

Asia Pacific

China

India

Japan

Southeast Asia

Rest of APAC

 

Central & South America 

Brazil 

Argentina

Rest of Central & South America 

 

Middle East and Africa

GCC

North Africa

South Africa

TABLE OF CONTENT

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Contraceptive Drugs Market, By ProductType

7.1.  Contraceptive Drugs Market, by ProductType, 2021-2027

7.1.1.    Oral Contraceptive Pills

7.1.1.1.        Market Revenue and Forecast (2016-2027)

7.1.2.    Injectable Contraceptives

7.1.2.1.        Market Revenue and Forecast (2016-2027)

7.1.3.    Topical Contraceptives

7.1.3.1.        Market Revenue and Forecast (2016-2027)

Chapter 8.  Global Contraceptive Drugs Market, By Application

8.1.  Contraceptive Drugs Market, by Application, 2021-2027

8.1.1.    15–24 years

8.1.1.1.        Market Revenue and Forecast (2016-2027)

8.1.2.    25–34 years

8.1.2.1.        Market Revenue and Forecast (2016-2027)

8.1.3.    35–44 years

8.1.3.1.        Market Revenue and Forecast (2016-2027)

8.1.4.    Above 44 years

8.1.4.1.        Market Revenue and Forecast (2016-2027)

Chapter 9.  Global Contraceptive Drugs Market, By End User

9.1.  Contraceptive Drugs Market, by End User, 2021-2027

9.1.1.    Homecare

9.1.1.1.        Market Revenue and Forecast (2016-2027)

9.1.2.    Hospitals

9.1.2.1.        Market Revenue and Forecast (2016-2027)

9.1.3.    Clinics

9.1.3.1.        Market Revenue and Forecast (2016-2027)

Chapter 10.      Global Contraceptive Drugs Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by ProductType (2016-2027)

10.1.2.  Market Revenue and Forecast, by Application (2016-2027)

10.1.3.  Market Revenue and Forecast, by End User (2016-2027)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.1.4.2.      Market Revenue and Forecast, by Application (2016-2027)

10.1.4.3.      Market Revenue and Forecast, by End User (2016-2027)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.1.5.2.      Market Revenue and Forecast, by Application (2016-2027)

10.1.5.3.      Market Revenue and Forecast, by End User (2016-2027)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by ProductType (2016-2027)

10.2.2.  Market Revenue and Forecast, by Application (2016-2027)

10.2.3.  Market Revenue and Forecast, by End User (2016-2027)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.2.4.2.      Market Revenue and Forecast, by Application (2016-2027)

10.2.4.3.      Market Revenue and Forecast, by End User (2016-2027)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.2.5.2.      Market Revenue and Forecast, by Application (2016-2027)

10.2.5.3.      Market Revenue and Forecast, by End User (2016-2027)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.2.6.2.      Market Revenue and Forecast, by Application (2016-2027)

10.2.6.3.      Market Revenue and Forecast, by End User (2016-2027)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.2.7.2.      Market Revenue and Forecast, by Application (2016-2027)

10.2.7.3.      Market Revenue and Forecast, by End User (2016-2027)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by ProductType (2016-2027)

10.3.2.  Market Revenue and Forecast, by Application (2016-2027)

10.3.3.  Market Revenue and Forecast, by End User (2016-2027)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.3.4.2.      Market Revenue and Forecast, by Application (2016-2027)

10.3.4.3.      Market Revenue and Forecast, by End User (2016-2027)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.3.5.2.      Market Revenue and Forecast, by Application (2016-2027)

10.3.5.3.      Market Revenue and Forecast, by End User (2016-2027)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.3.6.2.      Market Revenue and Forecast, by Application (2016-2027)

10.3.6.3.      Market Revenue and Forecast, by End User (2016-2027)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.3.7.2.      Market Revenue and Forecast, by Application (2016-2027)

10.3.7.3.      Market Revenue and Forecast, by End User (2016-2027)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by ProductType (2016-2027)

10.4.2.  Market Revenue and Forecast, by Application (2016-2027)

10.4.3.  Market Revenue and Forecast, by End User (2016-2027)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.4.4.2.      Market Revenue and Forecast, by Application (2016-2027)

10.4.4.3.      Market Revenue and Forecast, by End User (2016-2027)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.4.5.2.      Market Revenue and Forecast, by Application (2016-2027)

10.4.5.3.      Market Revenue and Forecast, by End User (2016-2027)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.4.6.2.      Market Revenue and Forecast, by Application (2016-2027)

10.4.6.3.      Market Revenue and Forecast, by End User (2016-2027)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.4.7.2.      Market Revenue and Forecast, by Application (2016-2027)

10.4.7.3.      Market Revenue and Forecast, by End User (2016-2027)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by ProductType (2016-2027)

10.5.2.  Market Revenue and Forecast, by Application (2016-2027)

10.5.3.  Market Revenue and Forecast, by End User (2016-2027)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.5.4.2.      Market Revenue and Forecast, by Application (2016-2027)

10.5.4.3.      Market Revenue and Forecast, by End User (2016-2027)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by ProductType (2016-2027)

10.5.5.2.      Market Revenue and Forecast, by Application (2016-2027)

10.5.5.3.      Market Revenue and Forecast, by End User (2016-2027)

Chapter 11.  Company Profiles

11.1.              Agile Therapeutics

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Allergan Plc

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Bayer AG

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              GlaxoSmithKline Plc

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Johnson & Johnson

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Piramal Healthcare

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Mylan N.V.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Pfizer Inc.

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Novartis AG

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Teva Pharmaceutical Industries Ltd

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

11.11.           HLL Lifecare ltd

11.11.1.               Company Overview

11.11.2.               Product Offerings

11.11.3.               Financial Performance

11.11.4.               Recent Initiatives

11.12.           Sanofi

11.12.1.               Company Overview

11.12.2.               Product Offerings

11.12.3.               Financial Performance

11.12.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Choose License Type

Checkout Inquiry Sample